Phio Pharmaceuticals (PHIO) Interest Expenses (2011 - 2025)
Phio Pharmaceuticals' (PHIO) quarterly Interest Expenses came in at $2.6 million in Q4 2025, up 4183.61% YoY from $61000.0 in Q4 2024, and up 2190.4% on a QoQ basis from -$125000.0 in Q1 2025.
Phio Pharmaceuticals (PHIO) Interest Expenses (2011 - 2025) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 15 years of Interest Expenses data on file, last reported at $2.6 million in Q4 2025.
- Quarterly Interest Expenses rose 4183.61% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$66000.0 (up 44.54% YoY) and the FY2025 annual result came in at $2.6 million, up 675.37% from the prior year.
- Interest Expenses grew to $2.6 million in Q4 2025, from -$125000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $2.6 million in Q4 2025 to a low of -$125000.0 in Q1 2025.
- A 5-year average of $163000.0 and a median of $34000.0 in 2022 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 373.53% — and 2025, when it jumped 4183.61%.
- Tracing PHIO's Interest Expenses over 5 years: stood at $22000.0 in 2021, then surged by 54.55% to $34000.0 in 2022, then sank by 373.53% to -$93000.0 in 2023, then soared by 165.59% to $61000.0 in 2024, then jumped by 4183.61% to $2.6 million in 2025.
- The last three Interest Expenses figures came in at $2.6 million (Q4 2025), -$125000.0 (Q1 2025), and $61000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Phio Pharmaceuticals | 14.06 Mn | 14.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.61 Mn |
| Dec 31, 2025 | 2.61 Mn |
| Mar 31, 2025 | -125,000.00 |
| Mar 31, 2025 | -125,000.00 |
| Dec 31, 2024 | 61,000.00 |
| Dec 31, 2024 | 61,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Jun 30, 2024 | -2,000.00 |
| Mar 31, 2024 | -53,000.00 |
| Mar 31, 2024 | -53,000.00 |
| Dec 31, 2023 | -93,000.00 |
| Dec 31, 2023 | -93,000.00 |
| Sep 30, 2023 | 35,000.00 |
| Sep 30, 2023 | 35,000.00 |
| Jun 30, 2023 | 35,000.00 |
| Jun 30, 2023 | 35,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Dec 31, 2022 | 34,000.00 |
| Dec 31, 2022 | 34,000.00 |